Quanterix Corporation Insider Trading Activity

Insider Trade Summary

Grant/Award: 78,162 shares

Grant/Award 3 txns

Insider LAI GOLDMAN MYLA

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	50,758	$0.00	$0.00
Grant/Award	Common Stock	2,940	$0.00	$0.00
Grant/Award	Common Stock	24,464	$0.00	$0.00

Holdings After Transaction: Stock Option (right to buy) — 50,758 contracts (Direct); Common Stock — 27,404 shares (Direct)

Footnotes (4)

1. F1. Received in exchange for 20,000 shares of Akoya Biosciences, Inc. ("Akoya") common stock in connection with the acquisition of Akoya by Quanterix on July 8, 2025. Dr. Lai-Goldman received: (a) 0.1470 of a share of Quanterix common stock and (b) $0.37 in cash, for each share of Akoya common stock. The closing price of the Quanterix common stock on July 8, 2025 was $6.54 per share. The closing price of the Akoya common stock on July 7, 2025 was $1.29 per share.
2. F2. Represents shares of stock issuable on vesting of restricted stock units. The restricted stock units vest as to one-third of the shares on each of July 8, 2026, July 8, 2027 and July 8, 2028.
3. F3. Includes 24,464 restricted stock units.
4. F4. The option vests as to one-third of the shares on July 8, 2026, and the remaining two-thirds of the shares vest monthly thereafter over two years in 24 successive equal installments.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 07/10/2025 - 08:39 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

LAI GOLDMAN MYLA

(Last) (First) (Middle)

C/O QUANTERIX CORPORATION

900 MIDDLESEX TURNPIKE

(Street)

BILLERICA MA 01821

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Quanterix Corp [ QTRX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
07/08/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	07/08/2025		A		2,940	A	(1)	2,940	D
Common Stock	07/08/2025		A		24,464(2)	A	$0.00	27,404(3)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$6.54	07/08/2025		A		50,758		(4)	07/08/2035	Common Stock	50,578	$0.00	50,758	D

Explanation of Responses:

1. Received in exchange for 20,000 shares of Akoya Biosciences, Inc. ("Akoya") common stock in connection with the acquisition of Akoya by Quanterix on July 8, 2025. Dr. Lai-Goldman received: (a) 0.1470 of a share of Quanterix common stock and (b) $0.37 in cash, for each share of Akoya common stock. The closing price of the Quanterix common stock on July 8, 2025 was $6.54 per share. The closing price of the Akoya common stock on July 7, 2025 was $1.29 per share.

2. Represents shares of stock issuable on vesting of restricted stock units. The restricted stock units vest as to one-third of the shares on each of July 8, 2026, July 8, 2027 and July 8, 2028.

3. Includes 24,464 restricted stock units.

4. The option vests as to one-third of the shares on July 8, 2026, and the remaining two-thirds of the shares vest monthly thereafter over two years in 24 successive equal installments.

Remarks:

	/s/ Brian Keane, as Attorney-in-Fact	07/10/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.